Harmony Biosciences Announces Plans To Initiate Phase 3 Registrational Study Of Pitolisant In Prader-Willi Syndrome Following End-Of-Phase 2 Meeting With The U.S. Food And Drug Administration
Portfolio Pulse from Benzinga Newsdesk
Harmony Biosciences has announced plans to initiate a Phase 3 registrational study of Pitolisant in Prader-Willi Syndrome following an end-of-Phase 2 meeting with the U.S. Food and Drug Administration.
July 20, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Harmony Biosciences is set to initiate a Phase 3 study of Pitolisant, which could potentially lead to a new product offering if successful.
The initiation of a Phase 3 study indicates that the company's product has shown promise in earlier trials and is now moving to a more advanced stage of testing. This could potentially lead to a new product offering if the study is successful, which would likely have a positive impact on the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100